EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
NASDAQ:AMRN

Amarin - AMRN Stock Forecast, Price & News

$1.14
+0.02 (+1.79%)
(As of 11/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.12
$1.15
50-Day Range
$1.07
$1.34
52-Week Range
$1.04
$3.82
Volume
2.19 million shs
Average Volume
3.65 million shs
Market Capitalization
$460.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.17

Amarin MarketRank™ Forecast

Analyst Rating
Hold
1.83 Rating Score
Upside/​Downside
90.1% Upside
$2.17 Price Target
Short Interest
Healthy
2.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.27) to ($0.18) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

643rd out of 1,038 stocks

Pharmaceutical Preparations Industry

313th out of 510 stocks

AMRN stock logo

About Amarin (NASDAQ:AMRN) Stock

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Receive AMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

AMRN Stock News Headlines

“The Bull Market Is Officially OVER” 
Bear market expert issues his top 10 stocks for 2023
Amarin (AMRN) Q3 2022 Earnings Call Transcript
Earnings Preview For Amarin Corp
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast
He predicted the 2020 crash a month before it happened…He predicted this year’s collapse back in January… And now, he’s issuing a brand-new warning – along with a unique solution.
Amarin Corporation plc (AMRN)
Amarin Corporation PLC
See More Headlines
Receive AMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

AMRN Company Calendar

Last Earnings
11/03/2021
Today
11/29/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMRN
Fax
N/A
Employees
560
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$2.17
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+90.1%
Consensus Rating
Hold
Rating Score (0-4)
1.83
Research Coverage
6 Analysts

Profitability

Net Income
$7.73 million
Pretax Margin
-19.04%

Debt

Sales & Book Value

Annual Sales
$583.19 million
Cash Flow
$0.06 per share
Book Value
$1.68 per share

Miscellaneous

Free Float
400,195,000
Market Cap
$460.37 million
Optionable
Optionable
Beta
1.82

Social Links


Key Executives

  • Mr. Karim Mikhail (Age 51)
    Pres, CEO & Director
    Comp: $1.19M
  • Dr. Steven B. Ketchum Ph.D. (Age 57)
    Pres of R&D, Exec. VP and Chief Scientific Officer
    Comp: $827.62k
  • Mr. Jason M. Marks J.D. (Age 46)
    Exec. VP, Chief Legal and Compliance Officer & Corp. Sec.
    Comp: $626.07k
  • Mr. Joseph T. Kennedy J.D.Mr. Joseph T. Kennedy J.D. (Age 54)
    Exec. VP of Strategic Initiatives & Gen. Counsel
    Comp: $980.18k
  • Mr. Aaron D. Berg (Age 59)
    Exec. VP & Pres of U.S.
    Comp: $745.52k
  • Mr. Thomas Charles Reilly (Age 50)
    CFO & Sr. VP
  • Dr. David Keenan
    Sr. VP of Technical Operations
  • Ms. Lisa M. DeFrancesco (Age 42)
    Sr. VP of Corp. Affairs & Investor Relations
  • Alina Kolomeyer
    Director of Communications
  • Mr. Jordan Zwick (Age 35)
    Sr. VP of Corp. Bus. Devel.













AMRN Stock - Frequently Asked Questions

Should I buy or sell Amarin stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMRN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRN, but not buy additional shares or sell existing shares.
View AMRN analyst ratings
or view top-rated stocks.

What is Amarin's stock price forecast for 2023?

6 brokers have issued 1 year price targets for Amarin's shares. Their AMRN share price forecasts range from $1.50 to $3.00. On average, they anticipate the company's share price to reach $2.17 in the next twelve months. This suggests a possible upside of 90.1% from the stock's current price.
View analysts price targets for AMRN
or view top-rated stocks among Wall Street analysts.

How have AMRN shares performed in 2022?

Amarin's stock was trading at $3.37 at the beginning of 2022. Since then, AMRN stock has decreased by 66.2% and is now trading at $1.14.
View the best growth stocks for 2022 here
.

When is Amarin's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our AMRN earnings forecast
.

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) posted its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.01. The biopharmaceutical company earned $142 million during the quarter, compared to analysts' expectations of $161.29 million. Amarin had a negative net margin of 21.72% and a negative trailing twelve-month return on equity of 14.92%. The firm's revenue was down 8.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.02) EPS.

What is John Thero's approval rating as Amarin's CEO?

43 employees have rated Amarin Chief Executive Officer John Thero on Glassdoor.com. John Thero has an approval rating of 93% among the company's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend.

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

Who are Amarin's major shareholders?

Amarin's stock is owned by a number of retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (2.12%), Kynam Capital Management LP (1.66%), SCP Investment LP (1.05%), ExodusPoint Capital Management LP (0.53%), Two Sigma Investments LP (0.50%) and 13D Management LLC (0.44%). Insiders that own company stock include David M Stack, John F Thero, Joseph S Zakrzewski, Michael Wayne Kalb, Olsen Per Wold and Steven B Ketchum.
View institutional ownership trends
.

How do I buy shares of Amarin?

Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $1.14.

How much money does Amarin make?

Amarin (NASDAQ:AMRN) has a market capitalization of $460.37 million and generates $583.19 million in revenue each year. The biopharmaceutical company earns $7.73 million in net income (profit) each year or ($0.23) on an earnings per share basis.

How many employees does Amarin have?

The company employs 560 workers across the globe.

Does Amarin have any subsidiaries?
The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.
Read More
How can I contact Amarin?

Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The official website for the company is www.amarincorp.com. The biopharmaceutical company can be reached via phone at (531) 669-9020 or via email at investor.relations@amarincorp.com.

This page (NASDAQ:AMRN) was last updated on 11/29/2022 by MarketBeat.com Staff